Patrick Mayes PhD

Patrick Mayes, PhD, is Director of Biology for the Immuno-Oncology and Combinations discovery performance unit at GlaxoSmithKline. He also serves as Early Development Leader for the anti-ICOS antibody program (GSK3359609), which is in Phase 1 clinical development. Dr Mayes previously managed antibody discovery efforts within the Immuno-Oncology and Combinations (IOC) Unit of GlaxoSmithKline where he developed novel therapeutic antibodies against a number of receptor targets, which modulate innate and adaptive immune responses.

These programs utilize a variety of different antibody platform technologies including Fc-engineered monoclonal antibodies (mAbs), bi-specific mAbs and domain antibodies (dAbs). A specific focus of the IOC unit at GSK is to identify and develop novel immune based drug combinations. Dr Mayes is involved in projects combining multiple immune targeted therapies as well as others combining immunotherapies with tumor targeted agents. He received his PhD in pharmacology from the University Of Pennsylvania School Of Medicine.